コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 oup (one CMV; one EBV-related posttransplant lymphoproliferative disorder).
2 risks, such as infectious mononucleosis and lymphoproliferative disorder.
3 entric Castleman disease (MCD) as a distinct lymphoproliferative disorder.
4 ing Burkitt lymphoma (BL) and posttransplant lymphoproliferative disorder.
5 ablation results in a fulminating and fatal lymphoproliferative disorder.
6 e rejection, sepsis, and posttransplantation lymphoproliferative disorder.
7 rious EBV diseases, including posttransplant lymphoproliferative disorder.
8 human malignancies, including posttransplant lymphoproliferative disorder.
9 ioimmunoblastic T cell lymphoma is a complex lymphoproliferative disorder.
10 the other as a result of posttransplantation lymphoproliferative disorder.
11 without increasing the risk of infection or lymphoproliferative disorder.
12 cytomegalovirus infection or posttransplant lymphoproliferative disorder.
13 graft-versus-host disease or posttransplant lymphoproliferative disorder.
14 of a previously undescribed KSHV-associated lymphoproliferative disorder.
15 ble, display fully penetrant female-specific lymphoproliferative disorder.
16 5 x 10(9)/L B-cells and no other signs of a lymphoproliferative disorder.
17 al B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.
18 skin, solid malignancies, and posttransplant lymphoproliferative disorder.
19 LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder.
20 g a possible explanation for female-specific lymphoproliferative disorder.
21 There were no cases of lymphoproliferative disorder.
22 , a life-threatening, virally induced B-cell lymphoproliferative disorder.
23 xperience higher incidence of posttransplant lymphoproliferative disorder.
24 stleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder.
25 al differences in the pathogenesis of B-cell lymphoproliferative disorders.
26 activation can be operative in these chronic lymphoproliferative disorders.
27 ted with neurological, gastrointestinal, and lymphoproliferative disorders.
28 acroglobulinemia, and 57 with B-cell chronic lymphoproliferative disorders.
29 of progression to late-onset posttransplant lymphoproliferative disorders.
30 ved Kaposi sarcoma (KS) and also for certain lymphoproliferative disorders.
31 introduced to reduce risk of posttransplant lymphoproliferative disorders.
32 er clinical pursuit in this and other B-cell lymphoproliferative disorders.
33 other cell types in blood from patients with lymphoproliferative disorders.
34 targeted therapy for CLL and related B-cell lymphoproliferative disorders.
35 sly undescribed role for monocytes in T-cell lymphoproliferative disorders.
36 increases in cardiovascular event risk, and lymphoproliferative disorders.
37 e role of chronic antigenic stimulation in B-lymphoproliferative disorders.
38 cells predisposes toward the development of lymphoproliferative disorders.
39 mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.
40 rvival factor, is elevated in autoimmune and lymphoproliferative disorders.
41 a viable target for mAb treatment of B-cell lymphoproliferative disorders.
42 educed intensity transplantation in indolent lymphoproliferative disorders.
43 clinical forms of Kaposi sarcoma and several lymphoproliferative disorders.
44 mplicated in the development of KSHV-induced lymphoproliferative disorders.
45 ion with HTLV-2 has not been associated with lymphoproliferative disorders.
46 ripheral and central) and haematological and lymphoproliferative disorders.
47 esis and angiogenic factors are increased in lymphoproliferative disorders.
48 portant in the progression or maintenance of lymphoproliferative disorders.
49 t and aggressive NHL as well as other B-cell lymphoproliferative disorders.
50 t been conclusively linked to development of lymphoproliferative disorders.
51 an give rise to Kaposi's sarcoma and several lymphoproliferative disorders.
52 s and in the neoplastic cells in most B-cell lymphoproliferative disorders.
53 ologic agent of Kaposi's sarcoma and several lymphoproliferative disorders.
54 ll leukemia/lymphoma (ATLL) and a variety of lymphoproliferative disorders.
55 h HTLV-2 has not been conclusively linked to lymphoproliferative disorders.
56 lantation and other immunodeficiency-related lymphoproliferative disorders.
57 non-Hodgkin lymphoma (NHL) and other B-cell lymphoproliferative disorders.
58 s leukemias and other myeloproliferative and lymphoproliferative disorders.
59 twork of target mRNAs associated with B-cell lymphoproliferative disorders.
60 somal locus 6q14.1, a mutational hot spot in lymphoproliferative disorders.
61 wel disease (IBD), rheumatoid arthritis, and lymphoproliferative disorders.
62 have also been found in patients with other lymphoproliferative disorders.
63 by its association with a variety of T-cell lymphoproliferative disorders.
64 targeted therapy for CLL and related B-cell lymphoproliferative disorders.
65 omplications, enteropathy, autoimmunity, and lymphoproliferative disorders.
66 is associated with an increased incidence of lymphoproliferative disorders.
67 enia, chronic EBV infection, and EBV-related lymphoproliferative disorders.
68 nctional polarization was examined in T-cell lymphoproliferative disorders.
69 ribute to the development of KSHV-associated lymphoproliferative disorders.
70 nctive entity "KSHV-associated germinotropic lymphoproliferative disorder."
73 expression in cases of human posttransplant lymphoproliferative disorder, a malignant condition asso
74 with B cell proliferation and posttransplant lymphoproliferative disorder after allogeneic bone marro
75 mia (WM) cases, and the clustering of B-cell lymphoproliferative disorders among first-degree relativ
77 CTLA-4-deficient (CTLA-4KO) mice develop a lymphoproliferative disorder and die within 4 weeks of b
78 ient in a functional Foxp3, exhibit a severe lymphoproliferative disorder and display generalized ove
79 of chronic organ rejection, post-transplant lymphoproliferative disorder and graft-versus-host disea
80 maturation but later developed a polyclonal lymphoproliferative disorder and signs of autoimmune dis
82 Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used t
83 distinction between MALT lymphoma and other lymphoproliferative disorders and led to the identificat
84 cells, and consequently develop progressive lymphoproliferative disorders and lupus-like autoimmune
85 s for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies amo
86 re was no association between posttransplant lymphoproliferative disorders and pretransplant MGUS.
87 n the suppression of host immunity in T-cell lymphoproliferative disorders and suggest that the targe
88 rstanding the viral associations in specific lymphoproliferative disorders and the molecular mechanis
89 levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether e
90 BL), HIV-associated lymphoma, posttransplant lymphoproliferative disorder, and nasopharyngeal carcino
91 tic large B cell, follicular, posttransplant lymphoproliferative disorder, and peripheral T cell lymp
92 ant pancreatic insufficiency, posttransplant lymphoproliferative disorder, and postsplenectomy sepsis
93 fic immunosuppression, including infections, lymphoproliferative disorders, and non-lymphoid malignan
98 The manifestations of posttransplantation lymphoproliferative disorders are myriad, from subtle fi
100 unusual presentation of posttransplantation lymphoproliferative disorder as unilateral leg swelling
101 Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpe
102 anular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disorder associated with rheumatoid
104 we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated
105 rviving CD28-deficient scurfy mice still had lymphoproliferative disorder, but their CD4 T cells show
106 y factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD).
107 entric Castleman disease (HIV-MCD) is a rare lymphoproliferative disorder caused by infection with hu
108 ymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived
109 ome of patients with CD30+ primary cutaneous lymphoproliferative disorders (CD30CLPD) and early mycos
111 3) functionally dysregulated, resulting in a lymphoproliferative disorder characterized by intraepith
112 Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly e
113 arge granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by the expans
114 ces an aggressive, fatal, and transplantable lymphoproliferative disorder characterized by the expans
115 ll chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder characterized by the surfac
116 ting immunoglobulins that occur secondary to lymphoproliferative disorders, chronic viral infections,
117 cell leukemia is an indolent, chronic B-cell lymphoproliferative disorder comprising approximately 2
118 response to immunotherapy, autoimmunity, and lymphoproliferative disorders, contributing overall to p
119 lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders display familial aggregati
120 Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated prod
121 sease describes a group of poorly understood lymphoproliferative disorders driven by proinflammatory
122 eated with CsA developed posttransplantation lymphoproliferative disorder during the follow-up period
124 Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD) in patients rece
126 nting a spectrum of primary cutaneous T cell lymphoproliferative disorders expressed CD25 and TGF-bet
128 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c
129 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c
130 cific prevalence and rates of progression to lymphoproliferative disorders for light-chain and conven
132 f the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations, or abe
133 ive with no single example of posttransplant lymphoproliferative disorder, graft-versus-host disease,
134 r, cladribine's impressive activity in other lymphoproliferative disorders has been generally underap
136 Bacteria can induce human lymphomas, whereas lymphoproliferative disorders have been described in pat
137 the development of EBV-associated lymphomas, lymphoproliferative disorders, hemophagocytic lymphohist
138 ase virus (MDV), a herpesvirus that causes a lymphoproliferative disorder in chickens, encodes a numb
140 ogren's syndrome in 22.5% of patients and to lymphoproliferative disorders in 28.7% of patients, and
142 fection that often develops into more severe lymphoproliferative disorders in immune-compromised anim
143 h the development of malignant lymphomas and lymphoproliferative disorders in immunocompromised indiv
146 undertaken to investigate the occurrence of lymphoproliferative disorders in patients treated with t
147 genesis of the interstitial lung disease and lymphoproliferative disorders in patients with CVID.
148 , a B cell lymphotrophic virus, is linked to lymphoproliferative disorders in people who have seconda
149 x 10(9)/L, and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/o
150 enic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphom
151 ought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic
152 which are associated with the development of lymphoproliferative disorders, including lymphomas, reac
153 EBV-infected B cells causes life-threatening lymphoproliferative disorders, including mostly germinal
154 s (EBV) infection is associated with several lymphoproliferative disorders, including posttransplant
155 miR-155 acts as an oncogenic miR in B-cell lymphoproliferative disorders, including Waldenstrom mac
156 tasizing neoplasms, polyclonal or monoclonal lymphoproliferative disorders, infections, interstitial
157 he pathogenesis of Kaposi's sarcoma (KS) and lymphoproliferative disorders, infects a variety of targ
158 CL) is an uncommon, indolent, chronic B-cell lymphoproliferative disorder involving the marrow and sp
161 The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood
162 or of interleukin-6 that is linked to B-cell lymphoproliferative disorders, is downregulated when eit
163 ge, the CD45 E613R (WEDGE) mutation led to a lymphoproliferative disorder (LPD) and a lupus-like auto
164 the wedge, the CD45 E613R mutation led to a lymphoproliferative disorder (LPD) and a lupus-like auto
165 y et al describe cases of an indolent T-cell lymphoproliferative disorder (LPD) of the gastrointestin
166 t an exhaustive search for pathogenic DNA in lymphoproliferative disorders (LPD) of the ocular adnexa
167 presents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP
169 ncy, all NPM-ALK Tg mice developed malignant lymphoproliferative disorders (mean survival, 18 weeks).
170 lobulin gene enhancer, develop a CD5+ B cell lymphoproliferative disorder mimicking human CLL and imp
171 s (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approx
172 C virus (HCV) is associated with the B-cell lymphoproliferative disorders mixed cryoglobulinemia (MC
174 ed multicentric Castleman disease (MCD) is a lymphoproliferative disorder most commonly observed in H
175 lticentric Castleman disease (KSHV-MCD) is a lymphoproliferative disorder, most commonly seen in HIV-
176 s (KSHV) is causatively linked to two B cell lymphoproliferative disorders, multicentric Castleman's
177 =2), chronic rejection (n=3), posttransplant lymphoproliferative disorder (n=1), graft dysmotility or
181 an Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disorder of childhood that occurs ma
182 nular lymphocytic (LGL) leukemia is a clonal lymphoproliferative disorder of CTL associated with cyto
185 h it establishes latency, and can also cause lymphoproliferative disorders of these cells manifesting
187 stein Barr virus-related posttransplantation lymphoproliferative disorder, one of which developed aft
188 oved QALYs, without increased posttransplant lymphoproliferative disorder or cytomegalovirus disease,
189 e CBL gene or the CBL-B gene can result in a lymphoproliferative disorder or hypersensitivity of lymp
190 that aberrant cell cycle control can lead to lymphoproliferative disorders or lymphoid malignancies.
192 e, proteinuria, c-peptide, viral infections, lymphoproliferative disorders or posttransplant diabetes
193 gent for Kaposi's sarcoma (KS) and two other lymphoproliferative disorders, primary effusion lymphoma
194 V) is known to be associated with 3 distinct lymphoproliferative disorders: primary effusion lymphoma
195 tein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-ba
197 Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD) after UCB transplant
199 tandard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified respo
200 based chemotherapy for a posttransplantation lymphoproliferative disorder (PTLD) and is disease-free
201 , including two patients with posttransplant lymphoproliferative disorder (PTLD) and one patient that
202 Barr virus (EBV)-related posttransplantation lymphoproliferative disorder (PTLD) associated with a ch
203 new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases after month 18
205 ssociated with development of posttransplant lymphoproliferative disorder (PTLD) following allogeneic
206 guished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD) from EBV(+)PTLD in r
208 the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presen
223 nded first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immu
224 pressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may be related with
225 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) remains a major caus
226 atment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the
227 scribe a form of plasmacytic post-transplant lymphoproliferative disorder (PTLD) that occurs in pedia
228 n EBV+ B cell lymphomas from post-transplant lymphoproliferative disorder (PTLD) to discover virally
230 aised the question of whether posttransplant lymphoproliferative disorder (PTLD), a complication of i
244 ith the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by
245 al Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial established
246 -Hodgkin's lymphoma including posttransplant lymphoproliferative disorder (PTLD; SIR = 54.3; 95% CI,
247 dition to a 0.4% incidence of posttransplant lymphoproliferative disorders (PTLD) and a 0.2% incidenc
248 e syndromes of EBV-associated posttransplant lymphoproliferative disorders (PTLD) and Kaposi's sarcom
251 between patients who develop posttransplant lymphoproliferative disorders (PTLD) early or late after
252 iated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in liver transplant
253 We previously reported that posttransplant lymphoproliferative disorders (PTLD) occurred more frequ
268 crolimus or cyclosporine) and posttransplant lymphoproliferative disorders related to chronic immunos
270 man granzyme B promoter in mice results in a lymphoproliferative disorder resembling adult T-cell leu
273 mouse spontaneously develops a CD5(+) B cell lymphoproliferative disorder similar to human chronic ly
274 orders such as systemic lupus erythematosus; lymphoproliferative disorders such as chronic lymphocyti
275 itis C virus (HCV) is associated with B-cell lymphoproliferative disorders such as mixed cryoglobulin
276 h characterized by a rapid lethal autoimmune lymphoproliferative disorder that complicates their use
277 4-deficient mice develop a lethal autoimmune lymphoproliferative disorder that is strictly dependent
278 y limits T-cell activation and the resultant lymphoproliferative disorder that occurs in CTLA-4-defic
279 rrier function, resulting in a more severe B-lymphoproliferative disorder that persisted into adultho
281 ell lymphomas represent a group of poor-risk lymphoproliferative disorders that have only recently be
282 e in vitro findings would be of relevance to lymphoproliferative disorders that occurred in patients
284 entric Castleman disease (HIV MCD) is a rare lymphoproliferative disorder, the incidence of which app
285 nd from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and
286 inued controversy about the relationships of lymphoproliferative disorders to each other, this case s
287 EBV is also associated with a variety of lymphoproliferative disorders, typically of B cell origi
288 g and could contribute to the development of lymphoproliferative disorders via constitutive NF-kappaB
291 ttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.6-5.7), 3.2 (1.
295 s may prove to be useful in the treatment of lymphoproliferative disorders, wherein clonal expansion
296 transplantation, mice died from this severe lymphoproliferative disorder, which was not transplantab
297 Hodgkin and Hodgkin lymphomas, as well as in lymphoproliferative disorders, which occur more commonly
298 nucleotide exchange factor Rasgrp1 develop a lymphoproliferative disorder with features of human syst
299 e in murine B cells leads to a CD5(+) B cell lymphoproliferative disorder with many of the features o
300 eview specifically discusses angiogenesis in lymphoproliferative disorders, with a special emphasis o
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。